14.22
+0.98(+7.40%)
Currency In USD
| Previous Close | 13.24 |
| Open | 13.41 |
| Day High | 14.35 |
| Day Low | 13.2 |
| 52-Week High | 37.08 |
| 52-Week Low | 6.36 |
| Volume | 2.42M |
| Average Volume | 3.1M |
| Market Cap | 2.02B |
| PE | -3.66 |
| EPS | -3.88 |
| Moving Average 50 Days | 10.73 |
| Moving Average 200 Days | 14.47 |
| Change | 0.98 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $594.98 as of September 07, 2025 at a share price of $14.22. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 3 years ago, it would be worth $1,030.43 as of September 07, 2025 at a share price of $14.22.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
GlobeNewswire Inc.
Aug 04, 2025 11:30 AM GMT
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GlobeNewswire Inc.
Jul 02, 2025 8:01 PM GMT
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the clos
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
GlobeNewswire Inc.
Jul 01, 2025 1:45 AM GMT
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pri